SCHEMBL5026569

SCHEMBL5026569

COc1ccc(C(=O)Oc2ccc([N+](=O)[O-])cc2)c2c3ccccc3n(C)c12

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.47
ALDH1A1 P00352 6/20 0.47
KDM4E B2RXH2 4/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
HPGD P15428 2/20 0.47
KMT2A Q03164 3/20 0.42
GAA P10253 2/20 0.42
PPARG P37231 1/20 0.41
TP53 P04637 1/20 0.40
MET P08581 1/20 0.40
MEN1 O00255 1/20 0.39
NPC1 O15118 1/20 0.39
LMNA P02545 1/20 0.39
BCL9 O00512 1/20 0.39
CTNNB1 P35222 1/20 0.39
ALOX15 P16050 1/20 0.38
MAPK1 P28482 1/20 0.38
PKM P14618 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5016430 0.86 GAA (0.43) MAPTALDH1A1KDM4ESMN1; SMN2HPGD
SCHEMBL5022811 0.85 MAPT (0.45) MAPTALDH1A1KDM4ESMN1; SMN2HPGD
SCHEMBL5022314 0.82 P2RX4 (0.44) MAPTALDH1A1KDM4ESMN1; SMN2HPGD
SCHEMBL4026837 0.79 MAPT (0.45) MAPTALDH1A1KMT2AMEN1LMNA
SCHEMBL5022812 0.76 MAPT (0.48) MAPTALDH1A1KDM4ESMN1; SMN2HPGD
SCHEMBL5022288 0.76 KDM4E (0.49) MAPTALDH1A1KDM4ESMN1; SMN2HPGD
SCHEMBL5023371 0.76 AR (0.43) MAPTALDH1A1KDM4ESMN1; SMN2HPGD
SCHEMBL5026662 0.76 PIK3R1 (0.45) MAPTALDH1A1KDM4ESMN1; SMN2HPGD
SCHEMBL6533698 0.76 TSPO (0.43) MAPTALDH1A1KDM4ESMN1; SMN2HPGD
SCHEMBL4030576 0.75 ALDH1A1 (0.47) MAPTALDH1A1SMN1; SMN2KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080146810-A1 NOVEL TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM GLENMARK PHARMACEUTICALS S.A. (CH) 2008-06-19 US disclosed
EP-1554262-B1 NOVEL TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM GLENMARK PHARMACEUTICALS LTD (IN) 2007-12-05 EP disclosed
US-7238725-B2 Tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them GLENMARK PHARMACEUTICALS LTD. (IN) 2007-07-03 US disclosed
US-20060178418-A1 Novel tricyclic compounds useful for the treatment of inflammatory and allergic disorders:process for their preparation and pharmaceutical compositions containing them GLENMARK PHARMACEUTICALS LTD. (IN) 2006-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146810-A1 NOVEL TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM LTC4S, TSLP, GPR119 MAPT 783/4885ALDH1A1 2372/4885KDM4E 4205/4885
US-20060178418-A1 Novel tricyclic compounds useful for the treatment of inflammatory and allergic disorders:process for their preparation and pharmaceutical compositions containing them LTC4S, TSLP, GPR119 MAPT 783/4885ALDH1A1 2372/4885KDM4E 4205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.